DE69521122T2 - 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze - Google Patents

2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze

Info

Publication number
DE69521122T2
DE69521122T2 DE69521122T DE69521122T DE69521122T2 DE 69521122 T2 DE69521122 T2 DE 69521122T2 DE 69521122 T DE69521122 T DE 69521122T DE 69521122 T DE69521122 T DE 69521122T DE 69521122 T2 DE69521122 T2 DE 69521122T2
Authority
DE
Germany
Prior art keywords
tetrahydro
acid addition
addition salts
benzazepine
benzazepine acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69521122T
Other languages
English (en)
Other versions
DE69521122D1 (de
Inventor
Brammer Hansen
Emil Amsler
Eugene Mcgraw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Addex Pharmaceuticals SA
Original Assignee
Cenes Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenes Ltd filed Critical Cenes Ltd
Application granted granted Critical
Publication of DE69521122D1 publication Critical patent/DE69521122D1/de
Publication of DE69521122T2 publication Critical patent/DE69521122T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69521122T 1994-03-16 1995-03-08 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze Expired - Lifetime DE69521122T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK31194 1994-03-16
PCT/DK1995/000106 WO1995025102A1 (en) 1994-03-16 1995-03-08 Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds

Publications (2)

Publication Number Publication Date
DE69521122D1 DE69521122D1 (de) 2001-07-05
DE69521122T2 true DE69521122T2 (de) 2002-03-07

Family

ID=8092128

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69521122T Expired - Lifetime DE69521122T2 (de) 1994-03-16 1995-03-08 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze

Country Status (10)

Country Link
US (1) US5658899A (de)
EP (1) EP0750616B1 (de)
JP (1) JPH09510222A (de)
AT (1) ATE201680T1 (de)
AU (1) AU1945495A (de)
DE (1) DE69521122T2 (de)
DK (1) DK0750616T3 (de)
ES (1) ES2158094T3 (de)
IL (1) IL112999A0 (de)
WO (1) WO1995025102A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
WO2002055063A2 (de) 2001-01-12 2002-07-18 Fumapharm Ag Fumarsäureamide
UA79248C2 (en) * 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
PL374799A1 (en) * 2002-08-05 2005-10-31 Sandoz Ag Novel salt and polymorphs of desloratadine hemifumarate
MXPA06002657A (es) 2003-09-09 2006-06-05 Fumapharm Ag Uso de derivados de acido fumarico para el tratamiento de insuficiencia cardiaca y asma.
RS63489B1 (sr) 2007-02-08 2022-09-30 Biogen Ma Inc Kompozicije i upotrebe za tretiranje multiple skleroze
US10569430B2 (en) 2011-09-16 2020-02-25 Persimmon Technologies Corporation Low variability robot
PT2872145T (pt) 2012-07-12 2022-05-26 Emalex Biosciences Inc Benzazepinas fundidas para o tratamento da síndrome de tourette
AU2014337140B2 (en) 2013-10-18 2020-01-30 Emalex Biosciences, Inc. Fused benzazepines for treatment of stuttering
KR20240046638A (ko) 2014-01-21 2024-04-09 퍼시몬 테크놀로지스 코포레이션 기판 이송 진공 플랫폼

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK23392D0 (da) * 1992-02-24 1992-02-24 Novo Nordisk As Heterocykliske forbindelser, deres anvendelse og fremstilling
US5470850A (en) * 1992-02-24 1995-11-28 Novo Nordisk A/S 2,3,4,5-tetrahydro-1H-3-benzazepines

Also Published As

Publication number Publication date
IL112999A0 (en) 1995-06-29
ES2158094T3 (es) 2001-09-01
DE69521122D1 (de) 2001-07-05
ATE201680T1 (de) 2001-06-15
EP0750616B1 (de) 2001-05-30
WO1995025102A1 (en) 1995-09-21
EP0750616A1 (de) 1997-01-02
JPH09510222A (ja) 1997-10-14
AU1945495A (en) 1995-10-03
DK0750616T3 (da) 2001-07-23
US5658899A (en) 1997-08-19

Similar Documents

Publication Publication Date Title
FI963070A (fi) Klooripyrimidiinivälituotteita
SE9504661D0 (sv) New compounds
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
ITFI910071U1 (it) Piastra per osso per la porzione distale dell'omero.
DK0998287T3 (da) Anvendelse af levobupivacain
DE69521122T2 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
BR9509975A (pt) Formulação farmacêutica
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
IT9047924A0 (it) Composizione per l'igiene orale.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
MD980129A (en) Antiherpetic remedy
BR9809286A (pt) Processos para redução de fibrinogênio
NO981135L (no) Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser
FR2700116B1 (fr) Application d'anticonvulsivants comme radioprotecteurs.
DE9403721U1 (de) Antiseptisches, chirurgisches Druckpflaster
UA31266A (uk) Лікувальний засіб "дінальгін"
ATE218366T1 (de) Pharmazeutische zusammensetzung enthaltend factor xiiia für nervenheilung
ES2116574T3 (es) 4-guanidinobutiramida para mejorar la circulacion de la sangre.
ITTO920656A1 (it) Sedia per operativita' chirurgica.
ITMI970682A1 (it) Procedimento per la preparazione di (s)-n-terbutil-1, 2, 3, 4- tetraidroisochinolin-3- carbossiammide
UA23368A (uk) Використання (1,1-діоксотіолан-3-іл) диктіокарбамату калію як антимікробного засобу
UA23119A (uk) Психотропhий засіб

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ADDEX PHARMACEUTICALS SA, GENF/GENEVE, CH